diphtheria, tetanus toxoid, pertussis & haemophilus b vaccine (Tetramune, DTP-Hib)

Indications: - active immunization of infants & children 2 months-5 years against diphtheria, tetanus, pertussis & haemophilus b when indications for DPT & HIB coincide Contraindications: 1) patients > 7 years of age 2) patients with cancer 3) immunodeficiency 4) children with a history of neurologic disorders 5) history of serious adverse reactions to pertussis vaccine 6) do not use for treatment of diphtheria, tetanus or pertussis infection 7) hypersensitivity to haemophilus b polysaccharide vaccine (thimerosal) pregnancy-category - safety in lactation - Dosage: Children 2 months-6 years (2-3 months recommended) 1) 0.5 mL IM on 3 occasions at 4-8 week intervals 2) reinforcing dose 1 year after 3rd injection Injection: 5 mL vials Pharmacokinetics: elimination: liver Adverse effects: 1) convulsions, screaming episodes, malaise, sleepiness, focal neurologic signs, shock, collapse, chills, erythema, induration, rash, urticaria, local tenderness, arthralgias, fever, swelling, warmth, increased risk of haemophilus b infections in the week following vaccination, allergic or anaphylactic reactions (rare) 2) all serious adverse reactions must be reported to the FDA Notes: If adverse reaction occurs, immunization should be completed with diphtheria & tetanus toxoid (dT, Td). A nodule may be present at the site of injection for a few weeks.

Related

Bordetella pertussis diphtheria Haemophilus influenzae tetanus

References

Kaiser Permanente Northern California Regional Drug Formulary, 1998

Components

haemophilus b vaccine; HIB vaccine (HibTITER, Hiberix) tetanus toxoid